Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

No results yet

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Citation:
Wadia U, Moore HC, Richmond PC, Levy A, Bell L, Pienaar C, Harvey J, Finucane C, van der Helder E, Bloomfield L, Cheng A, Effler P, Blyth CC. Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024. J Infect. 2025;90(4).

Keywords:
Children; Effectiveness; Hospitalisation; Immunisation; Nirsevimab; Real-world; Respiratory syncytial virus

Abstract:
Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.